A review. Apatinib mesylate is a new oral small mol. anti-angiogenesis inhibitor. Apatinib mainly blocks vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase activity by blocking the signal transduction pathway after vascular endothelial growth factor (VEGF) binds to its receptor. A series of pre-marketing clin. studies showed that apatinib has certain objective effectiveness and obvious survival benefits, a low incidence of serious adverse reactions, and good patient tolerability. Apatinib has been approved by the State Food and Drug Administration (CFDA) as a national class 1.1 new drug on Oct. 17, 2014 for third-line and above third-line treatment of advanced gastric cancer or adenocarcinoma of gastroesophageal junction. In order to better guide clin. reasonable and effective application of apatinib, the Chinese Society of Clin. Oncol. (CSCO) Anti-tumor Drug Safety Management Expert Committee organized multidisciplinary experts and scholars in related fields. With reference to the domestic use of other anti-angiogenesis inhibitors, we discussed them together and revised them several times, and finally formed this consensus for clinicians′ reference